Ultimo aggiornamento: agosto 27, 2026
Come vengono somministrate le cellule staminali per la perdita dell'udito?
Nei casi di perdita dell'udito associata a disfunzione dell'orecchio interno, precedente infezione, trauma, infiammazione, o alcune malattie genetiche, mesenchymal stromal cell therapy is being investigated as a regenerative approach. The method of administration must always be selected individually after determining the precise cause and location of the hearing impairment.
The inner ear is a small, delicate, and anatomically difficult-to-access organ. Direct local injection into or near its structures is an invasive procedure that may damage residual hearing, the cochlea, the vestibular apparatus, or adjacent neural structures. Per questo motivo, systemic intravenous administration may be considered as a less invasive method of introducing cells into the circulation.
The organs and tissues of the human body are interconnected through the vascular system and microcirculation. Following intravenous administration, the cells enter the bloodstream and interact with biological signals produced by injured, inflamed, or stressed tissues. These signals may include chemokines, citochine, molecole di adesione, e fattori di crescita.
Mesenchymal stromal cells carry receptors capable of responding to some of these molecular signals. This process is known as cellular homing O chemiotassi. Rather, molecular gradients may influence their adhesion, migrazione, and biological activity. research has identified signalling pathways such as SDF-1/CXCR4 as potentially relevant to cell migration toward injured cochlear tissues.
The possible therapeutic action is thought to depend mainly on paracrine signalling. Mesenchymal stromal cells release biologically active factors that may:
- modulate excessive inflammation;
- influence immune-cell activity;
- reduce cellular stress;
- support microvascular and endothelial function;
- stimulate survival and repair mechanisms in resident cells;
- promote a tissue environment more favourable to regeneration.
Depending on the underlying pathology, the affected structures may include cochlear hair cells, supporting cells, the stria vascularis, auditory neurons, the auditory nerve, or the inner-ear microcirculation. The potential cellular response may therefore differ considerably between hearing loss caused by inflammation or trauma and hearing loss resulting from an irreversible genetic defect.
Only very small numbers of endogenous progenitor cells normally circulate in peripheral blood, and their natural activity may be insufficient to reverse established chronic damage. In cell-therapy protocols, cells may therefore be isolated and expanded under controlled laboratory conditions to obtain a clinically defined dose. This process can take approximately seven days, depending on the source of the cells, the manufacturing protocol, and the required quality-control testing.
An intravenous dose—for example, 10 million or more cells
Revisione scientifica del caso
Ti piacerebbe capire se i programmi clinici sono attuali, recenti sviluppi della ricerca, o potrebbero esserlo gli approcci emergenti rilevante per la tua situazione individuale?
Condividi la tua domanda con il nostro team di ricerca scientifica e ricevi informazioni focalizzate sulle aree di ricerca attuale che potrebbero essere pertinente al tuo caso.
- Revisione delle informazioni fornite
- Informazioni rilevanti sulla ricerca e sul programma clinico
- Una risposta chiara focalizzata sulla tua situazione
Nessun obbligo. La tua domanda verrà esaminata in modo confidenziale.
Solo informazioni didattiche e di ricerca. Questo servizio no costituiscono un parere medico, diagnosi, prescrizione, o uno personalizzato raccomandazione terapeutica.
